TrialGynecologic oncology2009

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Russell J Schilder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.